✦ LIBER ✦

Comparing aromatase inhibitors in the absence of clinical trial results can be misleading

✍ Scribed by Aron Goldhirsch; Karen N. Price

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 57 KB
Volume: 95
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.20710

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In reply to “Comparing aromatase inhibit

In reply to “Comparing aromatase inhibitors in the absence of clinical trial results can be misleading” by Price et al.

✍ Generosa Grana 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

Estrogen reduction by aromatase inhibiti

Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: Results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane

✍ Radlmaier, Albert; Eickenberg, Hans U.; Fletcher, Matthew S.; Fourcade, Richard 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 799 KB

## BACKGROUND. The concept of estrogen withdrawal by an aromatase inhibitor in the treatment of benign prostatic hyperplasia (BPH) was assessed in a prospective, randomized, double-blind, placebo-controlled multicenter trial. METHODS. Two hundred and ninety-two patients with clinical symptoms of B

Comparing the efficacy of cyclooxygenase

Comparing the efficacy of cyclooxygenase 2–specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo-controlled trial

✍ Allan Gibofsky; Gary W. Williams; Frank McKenna; John G. Fort 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views

Rofecoxib, a specific inhibitor of cyclo

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip

✍ Grant W. Cannon; Jacques R. Caldwell; Peter Holt; Barry McLean; Beth Seidenberg; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 3 views

A multicenter, randomized, double-blind

A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial

✍ Daniel L. Rubin; Terry S. Desser; Richard Semelka; Jeffrey Brown; Hanh V. Nghiem 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views